(secondQuint)PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma.

 The primary objective of this phase 2 study is to assess objective response rate of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma.

 The secondary objective is to observe the duration of response,progression free survival,time to response,overall survival and safety of SHR-1210 in relapsed or refractory classic Hodgkin's lymphoma.

Pharmacokinetic index is also investigated in 12 patients.

.

 PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma@highlight

This is an open-label, multicenter, non-randomized, phase2 trial to evaluate efficacy and safety of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma.

 The primary objective is to assess ORR of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma.

